The broker Liberum repeated its ‘buy’ advice and 102p price target on Futura Medical PLC (AIM:FUM, OTC:FAMDF), which Monday provided an update on progress.
Liberum was heartened by both the regulatory and commercial progress being made by the developer of erectile dysfunction gel MED3000.
On the latter, Liberum said: “Expect more on the commercial strategy in 2022.”
It added: “Futura still has more work to do on this front, but today the company confirmed it is in advanced discussions for other commercial agreements with many interested parties, and expects to provide further updates during 2022.”
In early afternoon trading, the shares were up 6% at 33.39p.